METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib